Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Madhav Marda - Fidelity Investments Kunal Dhamesha - Macquarie Research Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Kunal Randeria - Axis Capital Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Harith Mohammed - Spark Institutional Equities Private Limited, Research Division Sumit Gupta - Centrum Broking Limited, Research Division Presentation Operator Good day, and welcome our quarter 2 fiscal year 2026 [indiscernible] Limited.
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CFO Conference Call Participants Neha Manpuria - Bank of America Kunal Dhamesha - Macquarie Group Madhav Marda - Fidelity Amey Chalke - JM Financial Bino Pathiparampil - Elara Capital Krishnendu Saha - Quantum Mutual Fund Tushar Manudhane - Motilal Oswal Abdulkader Puranwala - ICICI Securities Surya Patra - PhillipCapital Shashank Krishnakumar - Emkay Global Shrikant Akolkar - Nuvama Wealth Saion Mukherjee - Nomura Operator Ladies and gentlemen, good evening, and welcome to Quarter Four and Full Year FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] I now hand the conference over to Ms.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
